Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04686136 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 596
- Enrollment target
NCT04686136 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 596 participants.
The verdict
NCT04686136, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 596 participants
- Enrollment target
Study Summary
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
Interventions
- DRUG Atogepant 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2025-10-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04686136
The ClinicalTrials.gov registry entry for NCT04686136 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 596 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atogepant 60 mg is the first listed.
NCT04686136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04686136 about?
NCT04686136 is a clinical study titled "A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine". This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
What is the current status of trial NCT04686136?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 596 participants. The study started on 2021-02-19. Estimated completion is 2025-10-20.
What interventions are being tested in trial NCT04686136?
The interventions under investigation include: Atogepant 60 mg (DRUG).
Who is sponsoring clinical trial NCT04686136?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.